Do analysts prefer ADXN or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CTXR or ADXN?

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTXR or ADXN more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% Addex Therapeutics N/A -134.76% -106.00%

Do analysts recommend ADXN or PSTV?

Plus Therapeutics has a consensus price target of $51.75, suggesting a potential upside of 2,449.26%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend ADXN or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADXN or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.76% -106.00% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate ADXN or MBRX?

Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 288.05%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is ADXN or MBRX more profitable?

Addex Therapeutics' return on equity of -134.76% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.76% -106.00% Moleculin Biotech N/A -143.51% -24.53%

Addex Therapeutics (ADXN) Competitors

$3.40 +0.04 (+1.19%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.41 +0.01 (+0.29%)

As of 09/18/2026 06:39 PM Eastern

Compare

ADXN vs. CYCN, CTXR, PSTV, ZIVO, and MBRX

Should you buy Addex Therapeutics stock or one of its competitors? Addex Therapeutics's main competitors and comparable companies include Cyclerion Therapeutics (CYCN), Citius Pharmaceuticals (CTXR), Plus Therapeutics (PSTV), ZIVO Bioscience (ZIVO), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Addex Therapeutics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Addex Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclerion Therapeutics has higher revenue and earnings than Addex Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	19.91	-$8.12M	-$5.94	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Cyclerion Therapeutics	Neutral

Summary

Cyclerion Therapeutics beats Addex Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Citius Pharmaceuticals' return on equity of -59.57% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Addex Therapeutics	N/A	-134.76%	-106.00%

Citius Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Addex Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Addex Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Addex Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Addex Therapeutics	$210K	19.91	-$8.12M	-$5.94	N/A

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Addex Therapeutics. Citius Pharmaceuticals' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Addex Therapeutics	Neutral

Summary

Citius Pharmaceuticals beats Addex Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to Plus Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Addex Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Addex Therapeutics' return on equity of -134.76% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Plus Therapeutics	Neutral

Plus Therapeutics has a consensus price target of $51.75, suggesting a potential upside of 2,449.26%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Addex Therapeutics has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	19.91	-$8.12M	-$5.94	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Addex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

Addex Therapeutics beats Plus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to ZIVO Bioscience?

Addex Therapeutics (NASDAQ:ADXN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Addex Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	19.91	-$8.12M	-$5.94	N/A
ZIVO Bioscience	$15.85K	850.98	-$7.78M	-$1.40	N/A

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
ZIVO Bioscience	Neutral

ZIVO Bioscience's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Addex Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

Addex Therapeutics and ZIVO Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does Addex Therapeutics compare to Moleculin Biotech?

Addex Therapeutics (NASDAQ:ADXN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Addex Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

In the previous week, Moleculin Biotech had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 0 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.27 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Moleculin Biotech	Neutral

Addex Therapeutics has higher revenue and earnings than Moleculin Biotech. Addex Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	19.91	-$8.12M	-$5.94	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Addex Therapeutics' return on equity of -134.76% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 288.05%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Moleculin Biotech beats Addex Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.19M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.57	792.21	274.93	25.38
Price / Sales	19.91	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.73	10.53	10.46	6.33
Net Income	-$8.12M	$2.82B	$3.49B	$358.33M
7 Day Performance	-2.58%	1.69%	0.59%	1.12%
1 Month Performance	-25.60%	0.24%	-1.74%	-2.39%
1 Year Performance	-62.10%	3.95%	18.13%	5.35%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.8271 of 5 stars	$3.40 +1.2%	N/A	-62.1%	$4.19M	$210K	N/A	3	Positive News Short Interest Decrease
CYCN Cyclerion Therapeutics	0.9619 of 5 stars	$3.49 +3.9%	N/A	-79.1%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
CTXR Citius Pharmaceuticals	1.8186 of 5 stars	$0.56 0.0%	$5.00 +792.9%	-49.6%	$15.37M	N/A	N/A	20	Gap Up
PSTV Plus Therapeutics	1.4191 of 5 stars	$2.12 -2.3%	$51.75 +2,341.0%	-80.5%	$14.59M	N/A	N/A	20
ZIVO ZIVO Bioscience	N/A	$3.46 -15.7%	N/A	-75.4%	$14.56M	$15.85K	N/A	10	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. CYCN, CTXR, PSTV, ZIVO, and MBRX

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Summary

How does Addex Therapeutics compare to Plus Therapeutics?

Summary

How does Addex Therapeutics compare to ZIVO Bioscience?

Summary

How does Addex Therapeutics compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. CYCN, CTXR, PSTV, ZIVO, and MBRX

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Do institutionals & insiders have more ownership in ADXN or CYCN?

Is ADXN or CYCN more profitable?

Which has more volatility and risk, ADXN or CYCN?

Do analysts prefer ADXN or CYCN?

Which has better valuation & earnings, ADXN or CYCN?

Does the media refer more to ADXN or CYCN?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Do analysts prefer CTXR or ADXN?

Do institutionals and insiders have more ownership in CTXR or ADXN?

Is CTXR or ADXN more profitable?

Which has more risk and volatility, CTXR or ADXN?

Which has higher valuation & earnings, CTXR or ADXN?

Does the media prefer CTXR or ADXN?

Summary

How does Addex Therapeutics compare to Plus Therapeutics?

Is ADXN or PSTV more profitable?

Do insiders and institutionals hold more shares of ADXN or PSTV?

Does the media favor ADXN or PSTV?

Do analysts recommend ADXN or PSTV?

Which has stronger earnings and valuation, ADXN or PSTV?

Which has more volatility & risk, ADXN or PSTV?

Summary

How does Addex Therapeutics compare to ZIVO Bioscience?

Do analysts recommend ADXN or ZIVO?

Which has stronger earnings and valuation, ADXN or ZIVO?

Do institutionals and insiders hold more shares of ADXN or ZIVO?

Does the media favor ADXN or ZIVO?

Is ADXN or ZIVO more profitable?

Which has more volatility and risk, ADXN or ZIVO?

Summary

How does Addex Therapeutics compare to Moleculin Biotech?

Which has more risk and volatility, ADXN or MBRX?

Does the media prefer ADXN or MBRX?

Which has stronger earnings and valuation, ADXN or MBRX?

Is ADXN or MBRX more profitable?

Do analysts rate ADXN or MBRX?

Do insiders and institutionals have more ownership in ADXN or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools